Expression of integrin α‑6 is associated with multi drug resistance and prognosis in ovarian cancer

Abstract

Ovarian cancer is a serious threat to women's health. Multidrug resistance is a major cause of post-treatment relapse, metastasis, and even mortality. This characteristic severely restricts the survival of patients with ovarian cancer. Integrin α-6 (ITGA6) is a member of the adhesion molecule family that conducts signals through interactions between the extracellular domain and the matrix, serving important roles in cell adhesion-mediated drug resistance, which is considered to have a critical function in ovarian cancer drug resistance. The association between ITGA6 and ovarian cancer multidrug resistance has been investigated only rarely, to the best of our knowledge. Using RT-qPCR and immunohistochemistry, it was identified that ITGA6 is a central drug resistance gene, and that its expression was upregulated in cisplatin-resistant SKOV3 (SKOV3/DDP2), cisplatin-resistant A2780 (A2780/DDP) cells, and in 54 cases of drug-resistant tissues, as compared with in the controls. Furthermore, bioinformatics and text mining performed by Coremine Medical (http://www.coremine. com/medical/#search) confirmed that ITGA6 was significantly associated with ovarian cancer and drug resistance. Additionally, the high expression of ITGA6 is associated with a poor outcome. The present study provides the basis for further understanding the role of ITGA6 in the regulation of drug resistance in ovarian cancer, and demonstrates that it could be a potential marker for the prognosis of ovarian cancer.

Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro

“…The integrin subtypes α6, αV, β1, and β4 were also significantly increased under chronic everolimus exposure. α6 has been shown to induce cell motility and invasion and promote drug resistance [ 25 , 26 ] and might, therefore, be partially responsible for reactivating the tumor cell invasion cascade by everolimus. This integrin subtype was not further investigated, since in RT112 cells, it was not as strongly influenced by drug exposure as were other integrin subtypes.…”

Inhibited Long Non-Coding RNA OIP5-AS1 Elevated microRNA-92a to Suppress Proliferation and Metastasis of Ovarian Cancer Cells by Silencing ITGA6

“…Consistently, Song et al have unveiled that OIP5-AS1 was highly expressed in cervical cancer tissues [9]. A previous study has suggested that miR-92a was downregulated in breast cancer cells [16], and it has been identi ed that the expression of ITGA6 was increased in cisplatin-resistant SKOV3 and cisplatin-resistant A2780 cells, and also in drug-resistant tissues in comparison to the controls [18]. The relationship between OIP5-AS1 and clinicopathological characteristics of OC patients has been analyzed and we discovered that the high expression of OIP5-AS1…”

“…Nevertheless, the combined effect of OIP5-AS1 and miR-92a is still unexplored. Integrin alpha 6 (ITGA6) is a 150-kDa transmembrane protein [17] that has been revealed to be related to drug resistance and prognosis in OC [18]. However, the target relation between miR-92a and ITGA6 remains unexplored.…”

<p>MicroRNA-424 regulates cisplatin resistance of gastric cancer by targeting SMURF1 based on GEO database and primary validation in human gastric cancer tissues</p>

“…In previous studies, the Coremine database was widely used to find new therapeutic targets and mechanism analysis, especially in the analysis of chemotherapy resistance mechanisms. 53,54 Therefore, after cross-alignment by coremine database, LMO7, SMURF1, BCL2L1 and STAT3 were identified as the primary hubgenes. Afterwards, we continued to evaluate the association between hubgenes and the prognosis of gastric cancer patients by THPA.…”